Loading...

PE anti-mouse IL-2 Antibody

Pricing & Availability
Clone
JES6-5H4 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
JES6-5H4_PE_011108
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
  • JES6-5H4_PE_011108
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
503807 25 µg 83 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
503808 100 µg 220 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IL-2
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Detection1-3 or ELISPOT Detection4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization1,7: The Ultra-LEAF™ purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections2, in vivo capture7, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX™ Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
  3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
  4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
  5. Mo X, et al. 1995. J. Virol. 69:1288.
  6. Karulin A, et al. 2000. J. Immunol. 164:1862.
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
  9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
  10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
Product Citations
  1. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  2. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  3. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  4. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  5. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  6. Page N, et al. 2018. Immunity. 48:937. PubMed
  7. Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
  8. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  9. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  10. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  11. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  12. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  13. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  14. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  15. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  16. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
  17. White C, et al. 2015. J Immunol. 194:697. PubMed
  18. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  19. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  20. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  21. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  22. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  23. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  24. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  25. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  26. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  27. Li J, et al. 2021. Cell Reports. 34(11):108839. PubMed
  28. Marangoni F, et al. 2021. Cell. . PubMed
  29. Dolina JS, et al. 2020. Cell Rep. 107249:31. PubMed
  30. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  31. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  32. Wei H, et al. 2021. Malar J. 20:89. PubMed
  33. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  34. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  35. Shrivastava T, et al. 2021. Front Immunol. 12:641447. PubMed
  36. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  37. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  38. Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed
  39. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  40. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  41. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  42. Tanaka Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  43. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  44. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  45. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  46. Ma K, et al. 2022. iScience. 25:104347. PubMed
  47. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  48. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  49. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  50. Majedi FS, et al. 2020. Biomaterials. 252:120058. PubMed
  51. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  52. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  53. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  54. Nanishi E, et al. 2022. Commun Biol. 5:790. PubMed
  55. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  56. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  57. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  58. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  59. Liu Z, et al. 2022. Int J Nanomedicine. 17:1711. PubMed
  60. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  61. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  62. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  63. D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed
  64. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  65. Nanishi E, et al. 2023. NPJ Vaccines. 8:18. PubMed
  66. Shi X, et al. 2023. iScience. 26:106143. PubMed
  67. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
  68. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
RRID
AB_315301 (BioLegend Cat. No. 503807)
AB_315302 (BioLegend Cat. No. 503808)

Antigen Details

Structure
Cytokine; 15-30 kD (Mammalian)
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.

Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
UniProt
View information about IL-2 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account